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thromboembolism (VTE) following treatment for a
first unprovoked VTE
Joie Ensor1*, Richard D Riley1, David Moore1, Susan Bayliss1, Sue Jowett2 and David A Fitzmaurice3Abstract
Background: Venous thromboembolism (VTE) is a chronic disease, with fatal recurrences occurring in 5% to 9% of
patients, yet it is also one of the best examples of preventable disease. Prognostic models that utilise multiple
prognostic factors (demographic, clinical and laboratory patient characteristics) in combination to predict individual
outcome risk may allow the identification of patients who would benefit from long-term anticoagulation therapy,
and conversely those that would benefit from stopping such therapy due to a low risk of recurrence. The study will
systematically review the evidence on potential prognostic models for the recurrence of VTE or adverse outcomes
following the cessation of therapy, and synthesise and summarise each model’s prognostic value. The review has
been registered with PROSPERO (CRD42013003494).
Methods/design: Articles will be sought from the Cochrane library (CENTRAL, CDSR, DARE, HTA databases),
MEDLINE and EMBASE. Trial registers will be searched for ongoing studies, and conference abstracts will be sought.
Reference lists and subject experts will be utilised. No restrictions on language of publications will be applied.
Studies of any design will be included if they examine, in patients ceasing therapy after at least three months’
treatment with an oral anticoagulant therapy, whether more than one factor in combination is associated with the
risk of VTE recurrence or another adverse outcome. Study quality will be assessed using appropriate guidelines for
prognostic models. Prognostic models will be summarised qualitatively and, if tested in multiple validation studies,
their predictive performance will be summarised using a random-effects meta-analysis model to account for any
between-study heterogeneity.
Discussion: The results of the review will identify prognostic models for the risk of VTE recurrence or adverse
outcome following cessation of therapy for a first unprovoked VTE. These will be informative for clinicians currently
treating patients for a first unprovoked VTE and considering whether to stop treatment or not for particular
individuals. The conclusions of the review will also inform the potential development of new prognostic models
and clinical prediction rules to identify those at high or low risk of VTE recurrence or adverse outcome following a
first unprovoked VTE.
Keywords: Meta-analysis, Prediction, Prognosis, Pulmonary embolism, Recurrence, Risk factors, Thromboembolism,
Venous thrombosis* Correspondence: j.ensor@bham.ac.uk
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Venous thrombosis is a chronic disease, and recurrent
events are fatal in approximately 5% to 9% of patients
[1]. Most recurrences are easily preventable using
antithrombotic therapy, and it is therefore of great im-
portance that demographic, clinical or laboratory patient
characteristics associated with an increased risk of recur-
rence or adverse outcome are identified; such character-
istics are called prognostic factors [2]. For example,
previous studies suggest the risk is low among patients
with venous thromboembolism (VTE) provoked by sur-
gery, trauma, immobilization, pregnancy or female hor-
mone intake, whereas it is higher among those with
unprovoked thrombosis [3]. Stratification of patients
with unprovoked VTE according to their recurrence risk
might also be achieved on the basis of clinical risk fac-
tors such as gender, comorbidities or weight, or by
measuring laboratory markers of thrombophilia such as
factor V Leiden, the prothrombin mutation, natural co-
agulation inhibitor deficiencies, elevated coagulation fac-
tors and antiphospholipid antibodies [1,4-6]. More
recently efforts have been made to utilise global coagula-
tion markers, including D-dimer, as prognostic tools
[1,4].
Prognostic factors have a wealth of potential uses [2].
For example, they identify groups of patients at highest
risk of recurrence and thus inform prevention therapy,
patient counselling and policies; they can be combined
within a prognostic model to predict individual outcome
risk for individuals; they allow clinicians to monitor po-
tential changes in treatment response and outcome risk;
they may reveal the causal pathway between onset and
recurrence of VTE; they are potential adjustment and
confounding factors in randomised trials and observa-
tional analyses; and they inform sample size and ran-
domisation strategies in future trials [2].
Though there has been significant interest in the iden-
tification of prognostic factors for VTE recurrence, there
has been less progress in the development of prognostic
models. Prognostic models use multiple prognostic fac-
tors in combination to estimate outcome risk for an in-
dividual, based on their specific set of prognostic factor
values [7]. Clinicians could potentially utilise the pre-
dicted risk from such models to decide when it is safe to
stop therapy (often referred to as a clinical prediction
rule) [1,4].
Our work aims to systematically review all the evi-
dence for current prognostic models for VTE recurrence
and adverse outcome following cessation of therapy for
a first unprovoked VTE. The findings should inform
clinical practice and patient care by identifying demo-
graphic, laboratory and clinical characteristics that show
consistent evidence of prognostic value when adjusted
for other prognostic factors, and by summarising thecurrent prognostic models and their predictive perform-
ance. It will also inform further research of prognostic
factors and models in this clinical area, including the de-
velopment of a new clinical prediction rule being under-
taken by the authors.Research aims
This systematic review will identify and summarise stud-
ies of any design examining prognostic models (and clin-
ical decision rules based on such models) that utilise
multiple prognostic factors in combination to predict
the risk of VTE recurrence and/or adverse outcome in
patients that have ceased therapy for a first unprovoked
VTE. The patients examined must, before cessation of
therapy, have received at least three months’ oral anti-
coagulant therapy.Methods/design
Selection criteria
Study design
This review will include studies of any design or system-
atic reviews that develop, compare or validate a prog-
nostic model (or clinical prediction rule based on a
model) utilising multiple prognostic factors to predict
the risk of recurrence of VTE or adverse outcome fol-
lowing cessation of therapy for a first unprovoked VTE.Patient group
This review will study patients aged ≥18 years with a
first unprovoked VTE where the patient has received at
least three months’ treatment with an oral anticoagulant
therapy. Studies with mixed populations (including those
outside of the remit) will be included provided that the
appropriate data for our defined group of patients is
extractable.Setting
Studies in any setting will be included.Potential prognostic models
Studies must report a prognostic model utilising mul-
tiple prognostic factors to predict the risk of recurrence
of VTE or adverse outcome following cessation of ther-
apy for a first unprovoked VTE.Primary and secondary outcomes of our review
The primary outcome for the review will be the predict-
ive accuracy of prognostic models, in relation to VTE re-
currence. Secondary outcomes will be their predictive
ability in relation to other adverse outcomes, including
mortality and bleeding.
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The following bibliographic databases will be searched:
Cochrane Library (Wiley) (to include the Cochrane
Database of Systematic Reviews, DARE, HTA Databases
and CENTRAL Register of Controlled Trials),
MEDLINE (Ovid) 1950 to 2012, MEDLINE In - Process
& Other Non-Indexed Citations (Ovid) to date and
EMBASE (Ovid) 1980 to 2012. Searches will use index
terms and text words that encompass the patient group
supplemented by terms relating to recurrence or adverse
outcome and prognostic factors (see sample MEDLINE
search in Appendix 1).
Publicly available trial registers will also be searched,
such as ClinicalTrials.gov, UK Clinical Research Network
Study Portfolio Database (UKCRN), WHO International
Clinical Trials Registry Platform and the metaRegister of
Controlled Trials (mRCT). Reference lists of all included
papers will be checked and subject experts will be
contacted. No restrictions on publication language or
date limits will be applied.
In addition, abstracts from the following national and
international conferences from 2005 onwards will be
hand searched to capture studies that are not yet fully
published:
 Haematology: International Society of Thrombosis
and Haemostasis (ISTH), American Society of
Haematology (ASH), European Haematology
Association (EHA), British Society of Haematology
(BSH)
 Cardiology conferences: British Cardiac Society
(BCS), American College of Cardiology (ACC),
European Society of Cardiology (ESC), American
Heart Association (AHA), American College of
Chest Physicians (ACCP)
Study selection
This will be a two-step process. Titles (and abstracts
where available) will initially be screened by two re-
viewers independently, using predefined screening cri-
teria. These are broadly based on whether studies: (i)
included patients with a first unprovoked VTE who re-
ceived a minimum of three months’ oral anticoagulation
therapy and (ii) developed or examined prognostic
models in relation to VTE recurrence or other clinical
outcomes. Full texts of any potentially relevant articles
will then be obtained and two reviewers will independ-
ently apply the full inclusion criteria. Any discrepancies
between reviewers will be resolved by discussion or by
referral to a third reviewer. Portions of non-English lan-
guage studies will be translated where necessary to facili-
tate interpretation and data extraction. The study
selection process will be documented using the PRISMA
flow diagram [8]. Any relevant systematic reviewsidentified will be screened for further primary studies.
Reference management software will be used to record
reviewer decisions, including reasons for exclusion.
Data extraction
Data will be extracted independently by two reviewers
using an in-depth piloted data extraction form. Disagree-
ments will be resolved through discussion or referral to
a third reviewer.
Data extraction will include the following variables:
 Study characteristics: for example, sample size,
country and year
 Study design characteristics: for example,
randomised controlled trial, prospective, risk of bias
and length of follow-up
 Patient characteristics: for example, summaries of
age, gender, family history and treatment details in
the sample
 Candidate prognostic factors considered: for
example, any thresholds used, methods of
measurement and timing of measurement post
cessation of therapy
 Outcome measures: for example, recurrence of
VTE, mortality and bleeding
 Statistical methods employed and how prognostic
factors included in the analysis were handled: for
example, continuous or dichotomised
 Prognostic models: for example, the final model
(its specification and included factors), how it
was developed, and any internal or external
validation performance statistics for
discrimination (such as the C statistic or area
under the curve) or for calibration (such as the
expected/observed events ratio), together with
their confidence intervals
Assessment of study quality
The quality (risk of bias) of any studies developing or
evaluating a prognostic model will be assessed using the
criteria described by Altman [9], and by PROBAST (pre-
diction study risk of bias assessment tool) if it is avail-
able before our assessments begin.
Particular elements to be considered include:
 Study design (such as whether it was a prospective
design, and whether prognostic factor and outcome
measurements were reliable)
 Sample size (such as whether there was a pre-
specified sample size consideration accounting for
numbers of events and multiple comparisons in
selection of factors, and how much data was
available for external validation)
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completeness of data, and whether imputation was
used)
 Statistical analysis (such as handling of continuous
variables, selection of possible factors, and use of
bootstrapping or shrinkage)
 Internal and external model validation (whether
model validations are reported and how these were
carried out)
Evidence synthesis
Any studies reporting a prognostic model will be
summarised narratively, in particular what variables
(prognostic factors) were included in the final model;
how the included variables were coded; what the specifi-
cation of the model was and how it produces an individ-
ual outcome probability or risk score; the reported
predictive accuracy of the model; and whether the model
was validated internally and/or externally, and if so how.
If multiple studies are found that validate the same
prognostic model, then calibration statistics (such as
expected/observed events) and discriminatory statistics
(such as the C statistic or area under the curve) will be
synthesised using the random-effects meta-analysis of
DerSimonian and Laird [10,11], to summarise the
model’s average performance across different settings
and its predicted performance in a future setting [7,12].
Economic evaluation
Systematic review of published cost-effectiveness studies
A systematic review will be undertaken to identify any
existing economic studies including cost-effectiveness
and decision model-based analyses evaluating the use of
a prognostic model (or clinical prediction rule based on
a model), compared to the absence of a prognostic model
(or clinical prediction rule). Outcomes to be considered
will include quality of life, costs and measures of cost-
effectiveness (for example, incremental cost-effectiveness
ratios). Studies will be identified based on the above pro-
posed systematic review search methods with the inclu-
sion of appropriate study design filters to identify a subset
of economic studies. Quality assessment of economic
evaluation studies will be performed using the criteria set
out by the Consensus on Health Economics Criteria list
[13], and model-based studies will be evaluated based on
the guidelines described by Philips et al. [14].
Discussion
It is anticipated that the results of our systematic review
and meta-analysis of existing studies will be a signifi-
cant step towards informing the clinical management of
patients receiving therapy after a first unprovoked VTE.
In particular, the results of the review will identifyprognostic models for the risk of VTE recurrence or ad-
verse outcome following cessation of therapy for a first
unprovoked VTE. These will be informative for clini-
cians currently treating patients for a first unprovoked
VTE and considering whether to stop treatment or not
for particular individuals. The review will also identify
areas where the evidence for or against particular candi-
date prognostic models is lacking, and this will lead to
recommendations for initiating additional prognostic
model development and validation.
The factors identified by this review as having import-
ant and consistent prognostic value will be considered
for inclusion in related research by the authors (UK Na-
tional Institute for Health Research HTA Project 10/94/
02). This related project aims to develop a prognostic
model and clinical prediction rule to identify a sub-
group of patients at low risk of VTE recurrence (in
whom it is considered safe to stop anticoagulation ther-
apy given for a first unprovoked VTE) and in contrast to
identify a sub-group of patients at high risk of recur-
rence (for whom therapy should be continued). Our sys-
tematic review will identify any current prognostic
models in this area, and so – in the related project – we
will compare these existing models to the performance
of our own model. In the long term, if a suitable clinical
prediction rule is identified, this would then lead to the
comparison of groups of patients randomised to either
the clinical prediction rule or usual care. Therefore, our
systematic review is a crucial step towards the evidence-
based use of prognostic factors and risk prediction in pa-
tients with VTE considering cessation of therapy.
Appendix 1. Example search strategy for MEDLINE
Database: MEDLINE (Ovid) 1946 to November Week 3,
2012
Search strategy:
1. exp Venous Thromboembolism/
2. Pulmonary Embolism/
3. exp Venous Thrombosis/
4. (vte or dvt or pe).ti,ab.
5. deep vein thrombosis.ti,ab.
6. pulmonary embolism.ti,ab.
7. venous thrombo$.ti,ab.
8. or/1-7
9. (recurrence or recurr$ or re-occur$).ti,ab.
10. Recurrence/
11. exp Death/
12. (death$ or mortality).ti,ab.
13. Mortality/
14. clot$.ti,ab.
15. Hypertension, Pulmonary/
16. pulmonary hypertension.ti,ab.
17. post thrombotic syndrome.ti,ab.
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19. or/9-18
20. “Predictive Value of Tests”/
21. predict$.ti,ab.
22. exp Risk/
23. risk$.ti,ab.
24. prognos$.ti,ab.
25. or/20-24
26. exp Anticoagulants/
27. (anti-coagul$ or anticoagul$ or warfarin or
acenocoumarol or coumadin or coumarin or
phenprocoumon or sintrom or sinthrome or
jantoven or marevan or waran or nicoumalone or
dicoumarol or dicumarol).ti,ab.
28. (phenindione or dabigatran or ximelagatran or
apixaban or rivaroxaban or edoxaban or azd0837 or
ly517717 or ym150 or betrixaban or idraparinux).ti,
ab.
29. or/26-28
30. 8 and 19 and 25 and 29
Abbreviations
VTE: Venous thromboembolism.
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